The purpose of this study was to analyze the expression of 88.7 antigen and its implication in the low molecular weight B-Cell growth factor (LMW BCGF) proliferative pathway at the early stages of the human B-cell differentiation. After an overnight incubation in culture medium of B-cell precursor acute lymphoblastic leukemias (ALL). we demonstrated the presence of 88.7 antigen in 18 of 25 cases (72%). Such an incubation also induced a significant increase in the LMW BCGF responsiveness of ALL cells ( P < 0.03). In addition, we showed a significant correlation between 88.7 expression and the ability of pre-B ALL cells to respond to LMW BCGF. As previously described for normal B cells, the VER THE PAST 10 years, a number of lymphokines 0 have been described that influence human B cell activation (BCAF,),IV2 proliferation (IL-4, IL-2, interferon(s) [IFN], BCGF(S)),~-'~ and terminal differentiation (IL-4, IL-6, IFN, IL-2).I4-l7 The pleiotropic effects of a given interleukin on several steps of the B cell differentiation raise the question of the immunoregulatory pathway of these lymphokines.'8-20 How the binding of a given interleukin to the B cell surface leads to an intracellular signal remains in most cases an elusive issue. Nevertheless, it was clearly established that a first step of control is constituted by the acquisition of specific and functional receptors.*' Binding of the ligand to its receptor is followed by cytoplasmic events leading to either activation, proliferation, or terminal differentiation. The choice between these different pathways seems regulated by the qualitative and quantitative nature of previously delivered signals to the B-cell growth factors (BCGF(s)), and especially low molecular weight (LMW) BCGF, have a restricted effectessentially of growth factors-and restricted targets, namely, normal activated B cells (G1 of the cell cycle) and transformed B
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The reactivity to BCGF is linked to the acquisition of specific receptors. Studies on LMW BCGF have shown high and low affinity receptor sites on normal activated B cells. 26 Of particular interest are the works of Wormann et a1 and Uckun et a1 providing evidence of the LMW BCGF-dependent proliferation of pre-B acute lymphoblastic leukemias (ALL) cells and of the expression of LMW BCGF receptors on such cells.27-29 These data and other^^'.^^ suggest that reactivity to LMW BCGF may be acquired upon appropriate activation, all along the B-cell differentiation lineage.
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Abbreviations: NT, not tested; EM, bone marrow; PB, peripheral blood.
anti-B8.7 MoAb (IgGI) was purified on DEAE sephacryl column and coupled to biotin using the N-hydrosuccinimide ester procedure as described." Cells were successively stained with biotin-conjugated antLB8.7 MoAb for 30 minutes at 4OC, then with a mixture of phycoerythrin-conjugated streptavidin and of fluorescein isothiocyanate (F1TC)-conjugated antLCD10 MoAb (clone ALB2, IgG2) for 45 minutes at 4OC. Control samples were stained with biotinconjugated mouse IgGl (plus phycoerythrin labeled streptavidin) and FITC-conjugated mouse IgG2. Double labeled cells were analyzed after initial calibration of the cytometer with cells stained with each fluorochrome labeled antibody and the appropriate control. Dual colour labeling was performed before and after overnight incubation of cells, and only viable cells were gated for the analysis. Low molecular weight B-cell growth factor (LMW BCGF) purified by chromatography according to Mehta et a1,'O was purchased from Cellular Products (Buffalo, NY). These preparations contained no detectable IL-2 activity (less than 1 unit/mL), as assessed by the proliferation of the CTLL-2 murine T cell line. Recombinant IL-2 was provided by Boehringer Manheim (Meylan, France). Recombinant human interferon alpha (IFN-a) and interferon gamma (IFN-7) were obtained from Hoffman La Roche & Co (Neuilly sur Seine, France) and from Roussel Uclaf (Romainville, France), respectively. Recombinant tumor necrosis factor beta (TNF-8) was a gift from Dr J. Wietzerbin (Inserm 196, France).
Cells were cultured in RPMI 1640 medium (GIBCO, Grande Island, NY) containing 1% L-glutamine, 1% antibiotics, 1 mmol/L sodium pyruvate, and 2% selected heat inactivated fetal calf serum (FCS). Cells were cultured at 2 x IO' cells per well in 96-well flat bottomed microtest tissue culture plates Growth factors.
Proliferation assays.
(Falcon; Becton-Dickinson, Oxnard, CA) in the absence or presence of either LMW BCGF (10% or 20% vol/vol), IL-2 (10 or 20 U/mL), IFN-a, IFN-7 (from 10 to lo4 U/mL), or TNFB (from 10 to 100 mg/mL). During the last 12 hours of the 3-day culture period, cells were pulsed with 0.5 pCi3H thymidine per well (=18.5 kBq per well) (Oris Industrie, CEA, Saclay, France). 'H thymidine incorporation was measured in a liquid scintillation counter (Beckman Instruments, Paris, France). The antLB8.7 MoAb was generated by immunizing Biozzi's high responder mice against activated human B cells and fusing murine splenocytes to the NSI myeloma cell. The anti-B8.7 MoAb (IgGl) has been previously characterized and recognized a B-cell restricted activation antigen functionally related to the LMW BCGF re~eptor.'~ Ascitic fluids were produced in nude mice and used for indirect immunofluorescence tests. A purified form of this MoAb obtained on DEAE sephacryl column was used for inhibition assays. Cells were plated at 2 x IO' cells per well in the presence of various doses of antkB8.7 MoAb (from 2 to 30 pg/mL) and incubated for 1 hour before adding either LMW BCGF (10% vol/vol) or medium as control. Purified myeloma IgGl or anti-CD10 MoAb (clone ALBI) was used as IgGl control antibodies. After 3 days of culture, the proliferation of cells was tested by 'H thymidine incorporation.
Percentage of inhibition (%I) was calculated as follows:
Production and characterization of the anti-B8.7 MoAb.
Inhibition of LMW BCGF response by anti-B8.7 MoAb.
ANTIGEN EXPRESSION ON B-CELL PRECURSOR ALL
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RESULTS
Proliferative response to LMWBCGF of pre-B ALL cells.
Cells from 25 patients diagnosed for pre-B ALL were tested for their reactivity with LMW BCGF ( Table 2 ). In the absence of lymphokine addition, the spontaneous proliferation of cells ranged from 221 k 30 cpm (patient number EJect of overnight incubation on the level of LMWBCGF response of pre-B ALL cells. Previous reports indicated that overnight incubation of pre-B ALL cells in medium increases cell surface CD25 antigen expression, as well as their proliferative response to BCGF.** We thus tested the effect of such an incubation toward the reactivity of the 25 patient cells to LMW BCGF. Cells were incubated for 18 hours in RPMI 1640 medium supplemented with 10% FCS and washed, and viable cells were tested for their lymphokine sensitivity ( Table 2) . We observed that patients 1 to 6, who exhibited a weak reactivity to LMW BCGF at day 0, were still low responders at day 1 (Acpm e 1,666). In contrast, patients 7 to 25 with higher levels of responsiveness at day 0 generally exhibited an increase of their proliferative response after overnight incubation (1,996 < Acpm < 51,413). An increase of the proliferation in the presence of medium alone was observed for 1 1 patients (PN 1,7, 10 through 12, 17, 19 through 22, and 24). As tested by a statistical paired t test (Wilcoxon sum rank t test) on the 25 patient values, the increase of LMW BCGF responsiveness after incubation was significant ( P i .03), whereas the variations of the spontaneous proliferation were not ( P > .9). It should be noted that overnight incubation did not induce significant reactivity to other lymphokines tested (IFN-a, IFN-y, and IL-2) (data not shown). Thus, the preincubation of pre-B ALL cells resulted in a selective enhancement of their responsiveness to LMW BCGF.
Moreover, while the addition of 20% vol/vol instead of 10% vol/vol LMW BCGF induced an increase in the LMW BCGF-dependent proliferation of most patient cells, these variations did not affect the classification between the two groups of responders. Therefore, further investigations were carried out with 10% vol/vol LMW BCGF. Response to TNF-/3 of pre-B ALL cells. As TNF-/3 was shown to contaminate commercial LMW BCGF preparations at concentrations around 100 ng/mL, we investigated the effects of this cytokine on the proliferation of cells from 7 of our 25 patients (PN 9, 14, 17, 18, 20, 23, and 24). After overnight incubation, the cells were plated with various doses of TNF-/3 ranging from 10 to 100 ng/mL, or with 10% vol/vol LMW BCGF. As shown in Table 3 , TNF-/3 was unable to induce proliferation (Acpm < 1,500), whatever the doses used. In contrast, these patients exhibited a good response to LMW BCGF.
The cells from 25 patients with pre-B ALL were tested for their reactivity with the anti-B8.7 MoAb before and after an 18 hour incubation (Table 4 ). Most patients expressed B8.7 antigen before incubation, but generally at low level. After in vitro culture, the expression usually increased, whereas the magnitude of such an increase was low and varied from 3% (PN 10) to a maximum of 37% (PN 12). This increase of B8.7% was significant as tested by a paired t test (Wilcoxon t test) on the 25-patient panel (P < .001) and appeared independently of the variation of HLA DR, CDlO or CD20 antigen. CD23 absent from the pre-B ALL cells at day 0 was not induced at day 1 (data not shown).
Coexpression of B8.7 and CDlO antigens on pre-B ALL cells. Double staining analysis was performed on cells from patients 9, 14, 18, 20, 23, and 25 using biotin-conjugated antbB8.7 and FITC-labeled anti-CD10 MoAb, before and after overnight incubation. Results enable us to conclude that at least 95% of B8.7+ cells before and after incubation are CD10+. The results obtained for patient 25 are depicted in Fig 1 as a representative experiment . On day 0, 82% of cells were CD10+, B8.7-and 14% CD10+, B8.7+ (Fig 1B) . This latter percentage was increased and reached 35% after an 18-hour incubation (Fig 1D) . The B8.7+, CD10-population represented less than 5% of the cells before and after incubation. Because no significant modification of the number of viable cells was observed during incubation, the increase of the B8.7+, CD10+ population seems to be due either to a more intense expression or to an acquisition of B8.7 antigen at the blast cell surface.
Correlation between B8.7 expression and the response to LMW BCGF. The relationships between the level of B8.7 antigen and the level of LMW BCGF response at day 1 ( Fig  2) were examined. Thus, for each individual patient the Expression of B8.7 antigen on pre-B ALL cells.
percentage of B8.7+ cells was plotted versus the corresponding Acpm for the LMW BCGF response. We established a significant correlation between these two parameters ( R = .49, P c .02). This statistical analysis also underlines that high responders to LMW BCGF (patient plots above the correlation line) exhibit percentages of B8.7+ cells higher than 12%.
Inhibition of the LMW BCGF response by the anti-B8.7 MoAb. This test was performed on cells from three patients (PN 19, 23, and 24) after an 18-hour incubation in medium supplemented with 10% FCS. Cells were plated with various doses of antkB8.7 MoAb (from 2 to 30 pg/mL) and incubated for 1 hour at 37% before addition of either medium or 10% LMW BCGF for 3 days. Myeloma IgGl or antLCD10 MoAb were used as control antibodies. Percentage of inhibition was calculated as described in Materials and Methods. Results presented in Fig 3 show that the LMW BCGF proliferative response for the three patients was inhibited in a dose-dependent manner, while the inhibition reached different plateau values according to the patient. This plateau value seems to be dependent both on the intensity of LMW BCGF response and on the percentage of B8.7 positive cells. Myeloma IgGl or anti-CD10 MoAb were unable to significantly impair the LM W BCGF-dependent proliferation of these cells.
DISCUSSION
On mature B cells, it has been clearly established that BCGF(s) act essentially as growth factors able to sustain the progression/proliferation of preactivated B Currently, very little is known about the second messengers used by these factors, as well as the nature of their receptors. Nevertheless, specific receptors for both LMW BCGF and high molecular weight BCGF have been demonstrated by ligand binding experiments on normal B cells. Scatchard analysis revealed both high and low affinity receptor sites for LMW BCGF on these cells.'2,26 Their presence is linked to the ability of cells to respond to LMW BCGF. Studies on hairy cell leukemia, non-Hodgkin's lymphoma, and B-cell precursor ALL first demonstrated that LMW BCGFdependent proliferation is observed for a significant proportion of these More recently, the finding of receptors for LMW BCGF on these neoplastic cells has extended this notion and ruled out the possibility that LMW BCGF-dependent proliferation was due to other contami- Because the anti-B8.7 MoAb was able to inhibit this latter proliferative response, we proposed that B8.7 antigen was functionally related to LMW BCGF receptor. The complexity of normal B cell activation stages and regulatory signals did not allow us to rule out the possibility that anti-B8.7 MoAb mediates an indirect effect on the LMW BCGFdependent proliferation. So neoplastic B cells-essentially monoclonal cells-seem to be a good model to further investigate the relationship between B8.7 antigen and the LMW BCGF receptor. Such an investigation is of particular interest within the early stages of B cell differentiation. We therefore studied a group of 25 patients with pre-B ALL.
B-cell precursor ALL are believed to originate from normal B-cell progenitors allegedly arrested at different stages of B cell differentiation as indicated by B-cell restricted or associated antigen expre~sion.~'.~' The panel of 25 patients studied was essentially composed of HLA DR+, CDlO+, CD9+, CD19+ cells, a phenotype recovered on 70% of normal pre-B
We observed that in 18 of 25 patients (72%), cells responded to LMW BCGF (Acpm > 2,000). From patient to patient, the intensity of the proliferative response was extremely variable, and only 13 of 25 patients (56%) had a Acpm > 5,000, ranging from 6,264 to 35,622 cpm at day 0. This responsiveness was correlated neither with the intensity of spontaneous proliferation nor with any of the phenotypic or cytologic cell features. In addition, the response to LMW BCGF is not due to residual normal B cells since costimulation of cells with anti-IgM antibody does not modify the pattern of reactivity (data not shown).
As previously reported by Wormann et a],** an overnight incubation of pre-B ALL cells in medium increases the susceptibility of cells to LMW BCGF, we tested the effect of such an incubation on our patient cells. Indeed, we observed a better sensitivity of cells to LMW BCGF at day 1 (after incubation) than at day 0 (P -= .03). Addition of 20% LMW BCGF instead of 10% did not change this pattern of reactivity. In contrast to normal B cells, pre-B ALL cells exhibit a rather characteristic response to BCGF, since no proliferation in the presence of IL-2, IFN-a or IFN-7 is observed even after overnight incubation (reference 28 and Y. Richard, unpublished data, 1985) . These observations CDlO', 82% B8.7-, CD10'. and 4% B8.7-. CD10-at day 0; and of 35% B8.7+, CD10'. 57% B8.7-. CDlO'. and 7% B8.7-, CD10-at day 1.
Kehrl et al have demonstrated the contamination of the LMW BCGF commercial preparations by about 100 ng/mL of TNF-/3 (lymphotoxin) and shown that TNF-P as well as TNF-a was able to sustain proliferation of normal preactivated B ~e l l s .~~,~~ More recently, Digel et a1 have shown that cells from a number of B-cell type lymphocytic leukemia proliferate in the presence of TNF-/3.46 Based on these observations suggesting that all or part of the LMW BCGFdependent proliferation was due to contaminant TNF-P, we examined the ability of pre-B ALL cells to respond to TNF-a and 6. After overnight incubation, cells from patients 9, 14, 17,18,20,23, and 24 were cultured for 3 days in the presence of either TNF-a or / 3 (1 to 100 ng/mL) or with 10% vol/vol LMW BCGF. Essentially no TNF-dependent proliferation was observed in this test, whereas the cells still responded to the LMW BCGF. At doses up to 100 ng/mL, we frequently observed an inhibition of the spontaneous proliferative response (data not shown). These data strongly suggest that the proliferative response of pre-B ALL cells to T N F is lower and more infrequent than that to the LMW BCGF and is not sufficient by itself to induce the proliferation we observed with the LMW BCGF.
On the same panel of patients, we studied the expression of B8.7 antigen before and after incubation in medium. At day 0, the expression of B8.7 was low and rather infrequent. At day 1, the expression is clearly increased or enhanced, as shown in Table 3 . The increase is nevertheless extremely variable from patient to patient and the percentage and mean agreement with that of Uckun et al, who generally described a low number of LMW BCGF receptors and a wide interpatient variation, even after i n c~b a t i o n .~~ At day 1, 19 of 25 patients expressed more than 10% of B8.7+ cells. While it was difficult to ascribe phenotypic particularities to these patients or to the six remaining patients (PN 1,5,7,8, 10, and 13) , we observed that only one of these six patients (PN 10) (16%) was CD20+, whereas 8 out of the 19 other patients were CD20+ (42%). Such results did not allow us to evidence a significant correlation, although they may reflect the existence of two functional populations of cells. This indication is of particular interest in view of the normal B cell ontogeny, since acquisition of CD20 antigen follows the passage from stage I1 to a more differentiated stage (stage III).47
In a second step, we asked whether a correlation exists between the level of B8.7 antigen expression and the ability of cells to respond to the LMW BCGF. When individual percentages of B8.7+ cells were plotted versus the corresponding Acpm, we observed that a linear relationship between these two parameters is established ( r = .49, P < .02).
While the linear relationship is modest, this statistical analysis points out the fact that higher responders to the LMW BCGF (patient values above the correlation line) also express percentage of B8.7+ cells higher than 12%. This result strengthens the relationships we previously pointed out with normal B cells and B cell lines, between B8.7 expression and the LMW BCGF responsiveness. However, some of the low responders may express similar percentage of B8.7+ cells, suggesting that unknown intracellular events may alter this correlation. Similar observations have been reported by Uckun, when he compared the level of LMW BCGF responsiveness and the number of specific receptor sites. Keeping in mind the hypothesis of a functional link between B8.7 molecule and the LMW BCGF receptor, abnormalities in the post membrane transduction signal may be conciliable with the above data. Conversely, when B8.7 antigen is absent from the membrane and the cells responsive to LMW BCGF, we can suspect a low level of receptor sites undetectable in flow cytometry with the anti-B8.7 MoAb. According to the IL-2 receptor model, we can also speculate that antLB8.7 MoAb only recognizes the low affinity part of the LMW BCGF receptor. Moreover, similar to normal B cells, the anti-B8.7 MoAb has an inhibitory effect on the LMW BCGF dependent proliferation.
These latter data sustain the hypothesis of a functional implication of B8.7 antigen within the LMW BCGF network. We provided evidence on the B8.7 antigen expression in the early stages of B cell differentiation and of its functional link to the BCGF regulatory pathway as early as at the pre-B cell stage. This work underlines the interest of neoplastic B cells in the understanding of the cytokine networks.
of fluorescence at day 1 is still low. In contrast to the increase of B8.7, the Percentages of HLA DR, CDIO* and CD20 positive cells were stable ( Table 4 ), and that of 0 2 3 was always below 5% (data not shown). These observations are in 
